Chief Medical Officer Directorate
Pharmacy and Medicines Division

Scottish Government
Riaghaltas na h-Alba
gov.scot

T: 0131-244-2528
E: irene.fazakerley@gov.scot

IMMEDIATE MESSAGE TO:

1. Directors of Pharmacy
2. Medical Directors NHS Boards

23 April 2024

Dear Healthcare Professional,

DRUG ALERT CLASS 3 DRUG ALERT 14 2024 – CLASS 3 MEDICINES RECALL – ACTION WITHIN 5 DAYS – NEON HEALTHCARE LTD, SUPREFACT 1MG/ML SOLUTION FOR INJECTION (CHEPLAPHARM – CANADIAN LIVERY)

Please see drug alert for onward transmission as below

Could all Directors of Pharmacy please forward this alert to:-

- Community Pharmacists
- Hospital Pharmacists
- Primary Care Pharmacists

Please could Medical Directors arrange to forward this alert on to:-

- General Practitioners
- Accident & Emergency Departments
- Directors of Public Health
- Relevant Clinics
- Chief Executives of NHS Board

Thank you for your co-operation.

Yours sincerely

IRENE FAZAKERLEY
Medicines Policy Team

Medicines & Healthcare products Regulatory Agency

M E D I C I N E S R E C A L L

CLASS 3 MEDICINES RECALL

Action Within 5 Days
Pharmacy/Wholesaler Level Recall

Date: 23 April 2024 EL (24)A/14 Our Ref: MDR 191-04/24

Dear Healthcare Professional,

Neon Healthcare Ltd

Suprefact 1 mg/ml solution for injection (Cheplapharm – Canadian Livery) PL N/A

SNOMED Code N/A

Batch No	Expiry Date	Pack Size	First Distributed
3F022A	12/2024	2 multi-dose vials of 5.5ml	11 April 2024

Active Pharmaceutical Ingredient: Buserelin Acetate

Brief description of the problem
Neon Healthcare Ltd is recalling the specific batch mentioned in this notification as a precautionary measure. This is because the named batch of Suprefact 1mg/ml solution for injection is being distributed in packaging intended for the Canadian market by Cheplapharm, instead of the correct UK packaging by Neon Healthcare Ltd for Buserelin 1 mg/ml solution for injection.

Advice for healthcare professionals
Stop supplying the above batch immediately. Quarantine all remaining stock and return it to your supplier using your supplier's approved process.

Wholesalers are also requested to check stock of Buserelin 1 mg/ml solution for injection for any packs that match Suprefact 1 mg/ml solution for injection (MAH: Cheplapharm – Canadian Livery) as per the product images below.

Medicines & Healthcare products Regulatory Agency

Advice for patients
No further action is required by patients as this is a Pharmacy and Wholesaler level recall. Patients who experience adverse reactions or have any questions about the medication, should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.

Further Information
For medical information or stock control enquiries please contact: Neon Healthcare Ltd via Medinfo@neonhealthcare.com or +44 (0) 1992 926 330

Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

Yours faithfully

Defective Medicines Report Centre
10 South Colonnade
Canary Wharf
London
E14 4PU
Telephone +44 (0)20 3080 6574
DMRC@mhra.gov.uk